Longeveron
Life Science & Technology Park
1951 NW 7th Avenue, Suite 300
Miami
Florida
33136
United States
Tel: 305-342-9590
Website: http://www.longeveron.com/
About Longeveron
Longeveron is a regenerative medicine therapy company founded in 2014. Longeveron's goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company's research focus areas include Alzheimer's disease, Aging Frailty and the Metabolic Syndrome. Longeveron produces LMSCs in its own state-of-the-art cGMP cell processing facility.YEAR FOUNDED:
2014
LEADERSHIP:
Co-Founder and CSO: Joshua M. Hare, M.D.
87 articles with Longeveron
-
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
5/13/2022
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the first quarter ended March 31, 2022.
-
Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.
-
Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022Live conference call at 8:30 a.m. EST
5/9/2022
Longeveron Inc. today announced that the Company will release its first quarter 2022 financial results on Friday, May 13, 2022 before the open of the U.S. financial markets.
-
Longeveron Announces CEO Transition - May 09, 2022
5/9/2022
Longeveron Inc. announced the resignation of Chief Executive Officer Geoff Green, who is leaving the Company effective June 1st, 2022, to pursue new opportunities.
-
Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference
4/14/2022
Longeveron Inc. announced today its Chief Science Officer, Co-Founder, and Chairman, Joshua Hare, M.D., F.A.C.C., F.A.H.A. will be presenting at the Longevity Leaders World Congress in April.
-
Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical OfficerDr. Min will lead global clinical development and regulatory strategy
4/5/2022
Longeveron Inc. announced the addition of K. Chris Min, M.D., Ph.D. to the Longeveron executive leadership team in the role of Chief Medical Officer, effective April 4, 2022.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association
3/31/2022
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders, and other specific life-threatening conditions, announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer’s disease (AD) in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association.
-
Longeveron Presents at Second Euro-Geroscience Conference
3/24/2022
Longeveron Inc. announced that management presented at the Second Euro-Geroscience Conference, being held from March 24-25, 2022 virtually and in Toulouse, France, and at a pre-meeting task force.
-
Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference
3/15/2022
Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022.
-
Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
3/11/2022
Longeveron Inc. (NASDAQ: LGVN) (the “Company,” “Longeveron” or “we,” “us,” or “our”), a clinical stage biopharmaceutical company developing cellular therapies for chronic, aging-related and life-threatening conditions, today reported recent business highlights and key upcoming catalysts for 2022, and its financial results for the fourth quarter and full year 2021.
-
Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022
3/7/2022
Longeveron Inc. today announced that the Company will release its fourth quarter and year-end 2021 financial results on Friday, March 11, 2022 before the open of U.S. financial markets.
-
Longeveron to Present at Q1 Virtual Investor Summit Conference
3/2/2022
Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Q1 Virtual Investor Summit on Tuesday, March 8, 2022.
-
Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors
2/17/2022
Longeveron Inc. announced today the appointment of Todd Girolamo to its Board of Directors.
-
Longeveron to Participate in Phacilitate Advanced Therapies WeekLongeveron management will present live in multiple sessions at the Advanced Therapies Week at the Miami Beach Convention Center
1/25/2022
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will be speaking and participating in several panel and presentation sessions during Phacilitate’s Advanced Therapies Week from January 25-28, 2022 in Miami Beach, FL.
-
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
1/12/2022
Longeveron Inc. announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s DiseaseTrial designed to obtain safety and efficacy data of single and multiple dosing regimen
1/5/2022
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD).
-
Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference
1/4/2022
Longeveron Inc. announced that Geoff Green, Chief Executive Officer of Longeveron, will present at the H.C. Wainwright & Co. BioConnect 2022 Virtual Conference, and participate in a panel discussion moderated by Dr. Scott Gottlieb, the former commissioner of the U.S. Food and Drug Administration.
-
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
12/6/2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants.